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ABSTRACT
Objective: To conduct a fully independent and external
validation of a research study based on one electronic
health record database, using a different electronic
database sampling the same population.
Design: Using the Clinical Practice Research Datalink
(CPRD), we replicated a published investigation into the
effects of statins in patients with ischaemic heart disease
(IHD) by a different research team using QResearch. We
replicated the original methods and analysed all-cause
mortality using: (1) a cohort analysis and (2) a case-
control analysis nested within the full cohort.
Setting: Electronic health record databases containing
longitudinal patient consultation data from large numbers
of general practices distributed throughout the UK.
Participants: CPRD data for 34 925 patients with IHD
from 224 general practices, compared to previously
published results from QResearch for 13 029 patients
from 89 general practices. The study period was from
January 1996 to December 2003.
Results:We successfully replicated the methods of the
original study very closely. In a cohort analysis, risk of
death was lower by 55% for patients on statins,
compared with 53% for QResearch (adjusted HR 0.45,
95% CI 0.40 to 0.50; vs 0.47, 95% CI 0.41 to 0.53). In
case-control analyses, patients on statins had a 31%
lower odds of death, compared with 39% for QResearch
(adjusted OR 0.69, 95% CI 0.63 to 0.75; vs OR 0.61,
95% CI 0.52 to 0.72). Results were also close for
individual statins.
Conclusions: Database differences in population
characteristics and in data definitions, recording, quality
and completeness had a minimal impact on key statistical
outputs. The results uphold the validity of research using
CPRD and QResearch by providing independent evidence
that both datasets produce very similar estimates of
treatment effect, leading to the same clinical and policy
decisions. Together with other non-independent
replication studies, there is a nascent body of evidence
for wider validity.
INTRODUCTION
In recent years, electronic patient health
records have emerged as an important new
tool for medical research. Numbers of
research publications based on analyses of
electronic record databases have increased
rapidly, and government-sponsored research
networks—such as the Observational Medical
Strengths and limitations of this study
▪ Previous comparisons of electronic health record
(EHR) databases have compared different patient
populations or have not been done by independ-
ent researchers. This is the first fully independ-
ent validation of a published EHR-based study
using a different EHR database sampling from
the same underlying population.
▪ Estimates obtained from Clinical Practice
Research Datalink (CPRD) for the treatment
effects of statins on mortality in patients with
ischaemic heart disease (IHD) were remarkably
similar to those from QResearch, providing a
degree of reassurance for clinicians, researchers
and policy-makers that findings using either PCD
would be essentially the same.
▪ There were some demographic and other differ-
ences between the CPRD and QResearch IHD
cohorts. Sensitivity analysis indicated that these
had only a minimal effect on the results.
▪ We were able to successfully replicate nearly all
the elements of the original QResearch study
using CPRD, but this would not have been pos-
sible without some input on methodological
detail from the authors of the original study.
▪ The results add to evidence for the wider validity
of the UK primary care databases, but cannot be
generalised to EHRs in other countries where the
data quality may be quite different.
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Outcomes Partnership (OMOP) in the US and
Canadian Network for Observational Drug Effect
Studies (CNODES)—have been established to advance
research based on electronic records.
Globally, some of the largest and most detailed
sources of electronic patient data are the UK ‘primary
care databases’ (PCDs), some of which contain detailed
data on all primary care consultations for millions of
patients and span more than two decades. The three
major UK PCDs are the CPRD1 (Clinical Practice
Research Datalink; formerly the general practice
research database (GPRD)), QResearch2 and The
Health Improvement Network3 (THIN). These PCDs,
and CPRD in particular, are used as a resource by
researchers throughout the world. A search on PubMed
reveals that the combined number of articles based on
data from these three PCDs published during 2000 was
41; during 2012, it was 172.
Despite the growing use of electronic datasets as
research tools, there remain concerns about the validity
of studies based on such data, including uncertainties
around data quality, data completeness and the potential
for bias from measured and unobserved confounders.
The validity of coding in the UK PCDs has received a
considerable amount of attention in the literature,4–7 in
particular the completeness of recording of consulta-
tions and disease diagnoses. The former has been found
to be generally high,4 whereas the coding of diagnoses
varies considerably by condition.6 The validity of data on
risk factors—such as blood pressure and cholesterol—
has received less attention,8–10 but is of particular
importance for PCD-based effectiveness studies, where
selection bias and non-random missing data have the
potential to produce misleading conclusions.8
An alternative approach to assessing the validity of
PCD-based studies is to compare the results with those
obtained from equivalent investigations conducted on
other independent datasets. This approach subsumes
concerns about the validity and completeness of the
underlying individual data values within the broader
question of whether such ﬂaws in the data make any dif-
ference to the ultimate conclusions drawn from the ana-
lysis. A number of studies have compared results
obtained from PCDs with those from pre-existing rando-
mised controlled trials (RCTs) of the same interven-
tion.11–13 However, the use of RCTs as a gold standard
for judging the validity of PCD-based studies is question-
able: results may differ due to the very different contexts
of RCTs and observational data; for example, drug
regimes, patient characteristics and use of additional or
combination medications may differ radically in the real-
world setting. Another approach to validating a
PCD-based study is to replicate the study in one or more
completely independent PCDs. Agreement of results,
although not proving validity, would imply that the con-
clusions do not depend on the data source. This is the
approach we take in the present paper. Several studies
have applied the same design protocol to more than
one database.14–19 In most cases, these databases have
covered different countries,15–19 different geographical
areas of the same country16 17 or different patient popu-
lations within a country,14 and also different kinds of
databases (eg, administrative claims data vs electronic
health records14). Some studies have reported consistent
ﬁndings across databases; others have found varying
results. In a study examining the heterogeneity of effect
estimates for 53 drug-outcome pairs across 10 US data-
bases (either claims data or electronic health records)
using two different study designs,14 only nine pairs were
consistent across databases in direction and statistical sig-
niﬁcance, with up to 19 pairs having effect estimates
ranging from signiﬁcantly increased risk to signiﬁcantly
decreased risk.
With these studies, it is not possible to determine
whether the heterogeneity of results is due to differ-
ences in data recording and quality between databases,
or to differences in demographics and health between
the covered populations. To address this, comparisons
are required involving databases that sample from the
same underlying patient population. A few studies fall
into this category, all based on UK PCDs. Bremner et al20
examined early-life exposure to antibacterials and subse-
quent development of hay fever by running identical
analyses on the CPRD and the Doctors’ Independent
Network (DIN-LINK). The two child cohorts proved
similar in all essentials and results of case-control ana-
lysis were similar for both, even extending to a signiﬁ-
cant association between antibacterial exposure and
development of hay fever disappearing after adjustment
for a number of consultations. Vinogradova et al21 exam-
ined the relationship between exposure to bisphospho-
nates and gastrointestinal cancers using QResearch and
CPRD data. They reported the two patient samples to be
similar in demographics, risk factors, comorbidities and
use of medications, and found no signiﬁcant associations
between bisphonosphonate use and various types of
cancers in either database.
Both of these studies, although informative, were
however conducted by research groups instrumental in
the development of the comparative PCD (DIN-LINK
and QResearch, respectively) and so lacked independ-
ence. The only fully independent studies are a series
of external validation studies using the THIN
database and risk prediction tools originally developed
using QResearch (eg, QRISK, QRISK2, QKidney,
QStatin).10 22 23 These studies applied the risk algo-
rithms previously derived using QResearch on patients
in THIN, and reported mostly good discriminative and
calibration properties. However, these studies did not
address the question of whether analysis of the two data-
bases would result in the same at-risk algorithm itself. In
this paper, we report what we believe to be the ﬁrst com-
pletely independent full replication of a published
research study based on one PCD, using a different PCD
that samples from the same population. Our overall aim
was to assess the extent to which the model parameters
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(in this case, treatment effects) derived using one PCD
would be identical to those derived using the other
PCD. We also examine a different clinical topic and
outcome from these previous replications.
METHODS
CPRD and THIN obtain their data from practices using
the Vision electronic record system, while QResearch
obtains data from practices using EMIS software. We felt
that comparisons would be most informative between
databases drawing data from different capture systems.
Across the time-period studied, two versions of EMIS
were in use, the more common24 being the text-based
EMIS LV system with navigation and data entry mainly
via the keyboard; EMIS PCS, which is Windows-based
with mouse control and drop-down menus, was intro-
duced from 1999. Vision was Windows-based throughout
the study period. A small-scale direct comparison of
EMIS LV and Vision indicated that coded data entry,
excepting prescribing information, was faster with Vision
and that more items were likely to be coded.25 Practices
running Vision have slightly higher achievement rates
for most Quality and Outcomes Framework (QOF) indi-
cators than practices running either version of EMIS,
even after controlling for differences in practice and
area characteristics.24 We had access to CPRD, and there-
fore chose to replicate a study previously conducted
using QResearch. CPRD and QResearch both draw data
from general practices spread throughout the UK—cur-
rently more than 600 practices each—and comparisons
to the national age-gender structure and prevalence
rates for common conditions mostly show good corres-
pondence for both datasets.26 27 For practical reasons,
we focused on studies of the effectiveness of medicinal
interventions and, after assessing the available studies,
chose to replicate an investigation into the effects of
statins on the mortality of patients with ischaemic heart
disease (IHD) by Hippisley-Cox and Coupland
(H-C&C).28 The methodological details provided in the
published paper were insufﬁcient on their own to allow
a close replication to be conducted, and we therefore
obtained additional details from the authors. We
requested purely factual information about the methods
used and did not share any of our analyses or results.
We replicated the methods of H-C&C as closely as pos-
sible, given the differences between the two databases.
All of the methods described below, including the study
period, variable speciﬁcations and analytical procedures,
are exact replications of those used in the original study,
unless indicated otherwise. We selected all practices in
CPRD that provided up to standard (UTS) data (UTS is
CPRD’s designation for data meeting their internal
quality standards) for the whole of the period from 1
January 1996 to 17 December 2003. We next identiﬁed
all patients with a ﬁrst diagnosis of IHD within this
period, based on the QOF business rules for 2004.29 We
excluded patients whose IHD diagnosis fell within the
ﬁrst 3 months of registration with their general practice
or was on or subsequent to their recorded date of death,
or who were prescribed statins prior to ﬁrst diagnosis.
We extracted data for these patients from the date of
IHD diagnosis up until 17 December 2003, or until the
date of death or exit from the practice, or the last
recorded date for practices that stopped providing data
before 17 December 2003, giving a maximum possible
length of follow-up postdiagnosis of just under 8 years.
Analysis
The main outcome was all-cause mortality, identiﬁed
through a record of death in the CPRD. Following
H-C&C, we conducted two main analyses: (1) a cohort
analysis and (2) a case-control analysis nested within the
full cohort. All analyses were conducted using R.30
Following H-C&C, statistical signiﬁcance was assessed
using p<0.01 (two tailed), but 95% CIs are reported in
tables and ﬁgures.
We made an a priori decision not to attempt to
‘improve’ on the analysis conducted by H-C&C, as our
speciﬁc aim was to determine whether the same results
and conclusions would emerge from using identical
methods on a different underlying dataset targeting the
same population.
Cohort analysis
The cohort analysis used a Cox proportional hazards
model to examine the effect of statin use on patient sur-
vival, with survival time determined by the time (in days)
between the date of ﬁrst diagnosis and date of death.
Patients who transferred out of their practice before death
or who were still alive at the end of the study period were
treated as censored observations. Statin exposure was used
as a time-varying covariate, with the period of exposure
from the date of ﬁrst prescription to when the statin was
stopped (estimated as the date of last prescription plus
90 days; intervening breaks in the use of statins were
ignored), or if not stopped until the end of the study
period, date of death or date of transfer out of practice.
Covariates adjusted for in the analysis were year of diagno-
sis, gender, comorbidities (diabetes, hypertension, myocar-
dial infarction, congestive cardiac failure and cancer), and
age (coded as 0–44, 45–54, 55–64, 65–74, 75–84, 85–94 or
≥95), smoking (ever smoked, never smoked, not
recorded) and body mass index (BMI; coded as <25, 25–
30, >30 kg/m2) all at the date of diagnosis. The presence
of each comorbidity was indicated by a diagnosis in the
patient record (using the 2004 QOF business rules) and
coded as present/not present at the date of IHD diagnosis.
If smoking status or BMI was not recorded within 4 years
prior to diagnosis of IHD, we coded it as missing.
The analysis was undertaken using the R survival ana-
lysis package accounting for the clustering of patients by
practice and using the Huber-White robust estimate of
SE. The proportional hazards assumption was checked
graphically and with a test for proportional hazards.
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Nested case-control study
The nested case-control analysis compared all patients
from the cohort who died during the follow-up period
(the cases) with a group of matched control patients
(also with IHD) who did not die. For each case, we
deﬁned an ‘index date’ as the date of death. We then
used an incidence density sampling procedure (as per
the original study; personal correspondence) to ran-
domly select four control patients for each case matched
on gender, year of IHD diagnosis and age (coded in
5-year age-bands). General practice was not used as a
matching variable. Controls were patients with IHD alive
at the time their matched case died (including patients
who themselves became cases at a later time-point). The
incidence sampling procedure allowed the same patient
to be selected as a control for more than one case, thus
providing a full set of four controls for each case, while
still producing unbiased estimates of risk.31
Statin exposure was based on the ﬁrst and last pre-
scription dates prior to the index date and coded into:
(1) currently taking statins (last prescription was within
90 days of the index date); (2) previously took statins
(last prescription more than 90 days prior to the index
date) and (3) has never taken statins. We did this for all
statins as a group and also separately for ﬁve different
types of statin (atorvastatin, cerivastatin, ﬂuvastatin, pra-
vastatin and simvastatin). For ‘all statins’, the last pre-
scription could be for a different statin type than the
ﬁrst; for individual statins, it had to be the same type.
One further formulation, rosuvastatin, was in use that
did not appear in the QResearch study. We included this
in the ‘all statins’ group but did not analyse it individu-
ally as only 22 patients had received the statin.
Analysis of the case-control study used conditional
logistic regression accounting for the matching of cases
with controls, to obtain ORs for the risk of death in rela-
tion to use of statins. We allowed for clustering by
general practice and used a robust estimate of SE, in
line with the cohort analysis. Covariates in the analysis
were smoking status, BMI and comorbidities, speciﬁed
as in the Cohort analysis but based on the index date
rather than the date of diagnosis. Additional covariates
in this analysis were the Townsend deprivation score for
the practice postcode (in national quintiles; H-C&C
used quintiles of patient-level Townsend scores) and use
of β-blockers, aspirin, ACE inhibitors and calcium
channel blockers, identiﬁed through the British
National Formulary32 chapter codes in the patient
record. Each medication was coded as either used or
not used prior to the index date but after the date of
IHD diagnosis. Interactions between use of statins and
each of gender, age (less than 75 vs 75 and over) and
diabetes were tested by adding interaction terms into
the model.
Sensitivity analysis
To replicate the original sensitivity analyses, we reran the
case-control study: (1) while excluding patients without
recorded values for BMI or smoking; (2) with the
sample restricted to patients without a diagnosis of
cancer; (3) with the sample restricted to patients
without diabetes, congestive cardiac failure or myocar-
dial infarction and (4) using only those cases who sur-
vived for at least 1 year after diagnosis of IHD and their
matched controls. The deﬁnitions of death and depriv-
ation were different in CPRD and to assess sensitivity to
this we repeated the cohort and case-control analyses
with the analyses restricted to practices for which
patient-level Ofﬁce of National Statistics (ONS) ofﬁcial
death dates and Townsend scores were available (58% of
practices and 60% of patients).
Our primary analysis replicated H-C&C in restricting
the sample to only those practices with data for the full
8-year period. However, inclusion criteria for
CPRD-based studies are generally patient-based rather
than practice-based, and include all individual patients
with UTS data for the analysis period (ie, from diagnosis
date to end of study, death or transfer out of practice),
and on this basis 61 458 patients from 577 CPRD prac-
tices could be included. We therefore repeated the main
analyses using this sample.
RESULTS
Comparison of patient cohorts
A higher number of practices contributed data to the
CPRD cohort: 224 compared with 89 for QResearch,
resulting in a total sample of patients with a ﬁrst diagno-
sis of IHD in the study period, after exclusions, of 34 925
compared with 13 029 (table 1; note that if the original
study were undertaken now, additional practices (with
their retrospective data) added to QResearch since 2006
would produce a more equivalently sized cohort).
Incidence cases per practice were considerably higher
for CPRD (on average, 242 compared with 190), possibly
implying that the included CPRD practices were gener-
ally larger, though a smaller proportion of CPRD
patients met the study inclusion criteria (64.4% vs 77%).
H-C&C provided descriptive statistics for only certain
covariates, and reported these in person-years rather
than counts. Total person-years of observations in CPRD
were 125 709 compared with 43 460 in QResearch.
QResearch included a greater proportion of person-
years from older patients (36.3% from patients aged 75
or over compared with 28.1%) and had a much higher
representation of congestive cardiac failure (14% com-
pared with 6.0%), but less hypertension (28.9% com-
pared with 35.9%). These ﬁgures imply some
demographic differences between the cohorts.
Table 2 reports mortality rates from the two studies by
various patient characteristics. Age-band speciﬁc mortal-
ity rates were higher in CPRD for all age-bands except
the youngest (0–44 years), although, owing to differing
age distributions, the overall mortality rates were very
similar (53.5/1000 person-years for CPRD compared
with 52.1 for QResearch). Mortality was slightly higher
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for women than for men in both datasets. In both
cohorts, diabetes and congestive cardiac failure were
associated with greatly increased death rates.
Survival analysis
The Kaplan-Meier survival curve, uncontrolled for any
covariates (ﬁgure 1), shows a clear survival advantage
Table 1 Descriptive statistics of the CPRD and QResearch samples
CPRD QResearch
Number of general practices in the study 224 89
All patients with a first diagnosis of IHD during the study period
(incidence rate per practice)
54 217 (242) 16 920 (190)
Number (%) of incident cases meeting the inclusion criteria 34 925 (64.4%) 13 029 (77.0%)
End of study status
Died 6725 (19.3%) 2266 (17.4%)
Alive 24 292 (69.6%) 9609 (73.8%)
Left before end of study 3908 (11.2%) 1154 (8.9%)
Total person years of observation 125 709 43 460
Person years % Person years %
Age band (years)
0–44 4997 4.0 824 1.9
45–54 16 506 13.1 3923 9.0
55–64 30 431 24.2 9270 21.3
65–74 38 365 30.5 13 636 31.4
75–84 28 082 22.3 11 827 27.2
85–94 7073 5.6 3744 8.6
≥95 255 0.2 235 0.5
Women 57 169 45.5 18 539 42.7
Men 68 540 54.5 24 920 57.3
No diabetes 114 949 91.4 39 814 91.6
Diabetes 10 760 8.6 3646 8.4
No hypertension 80 574 64.1 30 912 71.1
Hypertension 45 136 35.9 12 547 28.9
No congestive cardiac failure 118 209 94.0 37 391 86.0
Congestive cardiac failure 7501 6.0 6069 14.0
CPRD, Clinical Practice Research Datalink; IHD, ischaemic heart disease.
Table 2 Comparison of mortality rates in the Clinical Practice Research Datalink (CPRD) and QResearch cohorts: eligible
patients only
CPRD QResearch
Cohort
Person
years
Number of
deaths
Rate/1000
person-years 95% CI
Rate/1000
person-years 95% CI
All 125 709 6725 53.5 52.3 to 54.8 52.1 50 to 54.3
Age band (years)
0–44 4997 44 8.8 6.5 to 11.9 9.7 4.9 to 19.4
45–54 16 506 202 12.2 10.6 to 14.1 10.2 7.5 to 13.9
55–64 30 431 638 21.0 19.4 to 22.7 16.8 14.4 to 19.7
65–74 38 365 1639 42.7 40.7 to 44.8 32.8 29.9 to 36
75–84 28 082 2638 93.9 90.6 to 97.4 77.0 72.2 to 82.2
85–94 7073 1457 206.0 196.6 to 215.6 167.2 154.6 to 180.8
≥95 255 107 419.8 359.0 to 483.1 331.4 265.4 to 413.7
Women 57 169 3116 54.5 52.7 to 56.4 54.1 50.9 to 57.6
Men 68 540 3609 52.7 51.0 to 54.4 50.7 48 to 53.6
No diabetes 114 949 5835 50.8 49.5 to 52.1 49.7 47.5 to 51.9
Diabetes 10 760 890 82.7 77.6 to 88.1 79.0 70.4 to 88.7
No
hypertension
80 574 4241 52.6 51.1 to 54.2 50.8 48.3 to 53.4
Hypertension 45 136 2484 55.0 53.0 to 57.2 55.5 51.5 to 59.8
No CCF 118 209 5410 45.8 44.6 to 47.0 41.4 39.3 to 43.5
CCF 7501 1315 175.3 166.8 to 184.2 118.6 110.3 to 127.6
CCF, congestive cardiac failure.
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for patients taking statins, with a raw HR of 0.25 (95%
CI 0.23 to 0.27; table 3). At 6 years, the unadjusted sur-
vival rate for patients taking statins was 89%, versus 63%
for those not taking statins, remarkably similar to the
reported values of 89% and 66% for the QResearch
cohort.
The Cox proportional hazards model (adjusted for
the covariates gender, age, year of diagnosis, diabetes,
hypertension, congestive cardiac failure, myocardial
infarction, cancer, BMI and smoking) signiﬁcantly
departed from the proportional hazards assumption
when year of diagnosis was speciﬁed as a continuous
variable (p<0.01). Respecifying year of diagnosis as a
stratiﬁcation variable resolved this problem. The
adjusted HR was 0.45 (95% CI 0.40 to 0.50), very close
to the adjusted HR for QResearch patients of 0.47 (95%
CI 0.41 to 0.53) and representing a 55% lower risk of
death for patients on statins.
Case-control study
The case-control analysis included 6683 cases and 26 732
controls (for 42 cases, we were unable to ﬁnd matching con-
trols). The cases and controls were well matched in terms of
median age, gender and duration of IHD (table 4). They
were also very close in these respects to the patients in the
QResearch study. Compared with QResearch, slightly lower
percentages of cases and controls had received a prescrip-
tion for statins (16.6% vs 19.6% and 22.8% vs 25.4%,
respectively), though there were smaller differences in the
percentages taking them for more than 1 year. For com-
pleteness, online supplementary table A provides a compari-
son of the CPRD cases and controls on the unmatched
covariates in the analysis (not available for QResearch).
These show a good to acceptable balance on all covariates.
Patients who were currently on a statin had a signiﬁ-
cantly decreased rate of death compared with patients
who had never taken a statin in unadjusted (OR=0.57,
95% CI 0.53 to 0.62) and adjusted (OR=0.69, 95% CI
0.63 to 0.75) analyses (table 5). These ORs were very
close to those reported for QResearch (unadjusted
OR=0.53, 95% CI 0.46 to 0.61; adjusted OR=0.61, 95%
CI 0.52 to 0.72; ﬁgure 2). Patients who were previously,
but not currently, on a statin had a signiﬁcantly elevated
risk of death in unadjusted and adjusted analysis,
whereas H-C&C found a signiﬁcantly increased risk in
unadjusted analysis only.
In the case of individual statins, the QResearch study
reported signiﬁcant protective effects against risk of
death for current use of atorvastatin and simvastatin;
with CPRD we found the same, but also a protective
effect for pravastatin, which just failed to reach 1% sig-
niﬁcance in QResearch (p=0.013). For all ﬁve statins,
our current use OR point estimates were similar to those
from QResearch, though the larger CPRD sample pro-
duced narrower CIs. Like the original study, we found
no signiﬁcant effects in patients who were previously, but
not currently, on any individual statin, despite the
increased risk for all statins combined.
Effects of age, sex and diabetes on the effectiveness
of statins
Like H-C&C, we found no evidence for an interaction
between gender and statin use (p=0.84), or diabetes and
statin use (p=0.62). Unlike H-C&C, however, we did ﬁnd
a signiﬁcant interaction with age (p<0.001), with an
adjusted OR of 0.55 (95% CI 0.48 to 0.62) for people
aged less than 75 and 0.77 (95% CI 0.65 to 0.92) for
those aged 75 or over, indicating greater beneﬁt for
those under 75 years of age.
Results for sensitivity analyses
Repeating the sensitivity analyses from the original study,
we found that restricting the case-control sample to
patients with BMI and smoking status information, or to
those without cancer, or without a diagnosis of diabetes,
congestive cardiac failure or myocardial infarction made
very little difference to our results. Restricting the
sample to patients alive for at least 1 year after diagnosis
of IHD likewise made little difference (see online
supplementary ﬁgure A).
Restricting the CPRD sample to practices for which
patient-level Townsend scores and ONS ofﬁcial death
dates were available made no appreciable difference to
the results of either the cohort (HR 0.47, 95% CI 0.40 to
0.54) or case-control analyses (see online supplementary
ﬁgure B). Similarly, widening the sample to include all
patients with UTS data made little difference (cohort
study HR=0.43, 95%CI=0.39 to 0.47; for Case-Control ana-
lysis, see online supplementary ﬁgure C).
Figure 1 Kaplan-Meier plot showing survival of patients
taking statins compared with patients not taking statins,
uncontrolled for covariates; CPRD study.
Table 3 Unadjusted and adjusted HRs (95% CI) of risk of
death for patients taking statins compared with patients not
taking statins; Clinical Practice Research Datalink (CPRD)
and QResearch studies
CPRD QResearch
Unadjusted 0.25 (0.23 to 0.27) Not reported
Adjusted 0.45 (0.40 to 0.50) 0.47 (0.41 to 0.53)
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DISCUSSION
We conducted an independent replication of a primary
care database-based study using a different primary care
database, sampling from the same population. We repli-
cated the methods of the original study as closely as we
could and reached exactly the same clinical conclusions
concerning the effects of statins on mortality in all their
essentials. Not only that, our point estimates for the key
statistical parameters—the HR from the cohort analysis,
and the ORs from the nested case-control study—were
remarkably similar to those reported by the original study.
For the period under study, CPRD provided a much larger
sample than was included in the original QResearch study.
LIMITATIONS
While we were able to exactly replicate nearly all the ele-
ments of the original study, there were a few minor dif-
ferences due mainly to data speciﬁcations. The datasets
may have differed in the way in which all-cause mortality
is deﬁned, as both use their own bespoke algorithm. For
area deprivation, QResearch used Townsend quintile
deprivation scores at the patient-level, whereas these
scores were fully available in CPRD only at the practice
level, and for only 60% of the cohort at the patient-level.
We tested for the impact of these factors by running a
sensitivity analysis using the subset of CPRD patients for
which linked ONS data on the date of death and resi-
dential Townsend scores were available.
FINDINGS
We observed a number of differences between the
CPRD and QResearch cohorts, in particular eligibility
rates, age distributions and some comorbidities; hence,
there may have been some population differences
between the cohorts. Although both PCDs purport to
provide nationally representative coverage of the UK
population, only subsets of the practices in each were
included (those providing data for the whole study
period) and it may be that these differed in coverage:
for the time-period of the study QResearch included
more practices from the South and East of the UK33
than our CPRD cohort, whereas the latter included
higher concentrations of practices from London, the
North West and Scotland. It is also possible that record-
ing differences between the Vision and EMIS computer
software systems24 resulted in differential coding of some
comorbidities.
Despite these differences, all of our key results using
CPRD were very close to those based on QRresearch.
The cohort analysis returned remarkably similar values
Table 4 Comparison of cases and controls for CPRD
and QResearch studies
CPRD QResearch
Number of patients
Cases 6683 2266
Controls 26 732 9064
Median age in years
Cases 80 80
Controls 80 80
Male (%)
Cases 53.6 55.7
Controls 53.6 55.7
Median duration of IHD (months)
Cases 21.3 20.3
Controls 21.4 21.0
N (%) prescribed statins
Cases 1108 (16.6) 445 (19.6)
Controls 6083 (22.8) 2303 (25.4)
Of those prescribed statins, N (%) taking them for
>12 months
Cases 572 (51.6) 228 (51.2)
Controls 3398 (55.9) 1336 (58)
CPRD, Clinical Practice Research Datalink; IHD, ischaemic heart
disease.
Table 5 Unadjusted and adjusted ORs comparing cases and controls by type and use of statins, CPRD study
Unadjusted OR
(compared with
never used) 95% CI
Adjusted OR
(compared with
never used) 95% CI p Value
Used previously
Any statin 1.43 1.24 to 1.65 1.4 1.21 to 1.63 <0.001
Atorvastatin 1.15 0.92 to 1.45 1.18 0.94 to 0.50 0.158
Cerivastatin 0.59 0.43 to 0.83 0.67 0.48 to 0.94 0.02
Fluvastatin 0.77 0.50 to 1.19 0.89 0.56 to 1.40 0.611
Pravastatin 1.03 0.78 to 1.36 1.13 0.85 to 1.50 0.398
Simvastatin 1.02 0.87 to 1.19 1.07 0.91 to 1.26 0.385
Used currently
Any statin 0.57 0.53 to 0.62 0.69 0.63 to 0.75 <0.001
Atorvastatin 0.55 0.48 to 0.64 0.66 0.57 to 0.77 <0.001
Cerivastatin 0.48 0.30 to 0.77 0.59 0.36 to 0.96 0.0336
Fluvastatin 0.50 0.33 to 0.76 0.65 0.43 to 0.99 0.0468
Pravastatin 0.60 0.49 to 0.73 0.68 0.56 to 0.84 <0.001
Simvastatin 0.64 0.58 to 0.71 0.78 0.70 to 0.87 <0.001
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to H-C&C for the statin use HR, both with and without
control for covariates. Likewise, the nested case-control
study yielded a very similar estimate for the protective
effect of current statin use. Also, like H-C&C, we found
separate protective effects for current users of atorvasta-
tin and simvastatin. Another formulation, pravastatin,
was found to be protective using CPRD but just failed to
reach 1% signiﬁcance in the QResearch study, the differ-
ence most likely being due to the larger CPRD sample.
In both studies, evidence for an elevated risk of death
for patients who were previously, but not currently, on
statins was somewhat at odds with the results for individ-
ual statins. However, cerivastatin was withdrawn from the
market in 2001, in the middle of the study period,34
which may have had a complex impact on these results,
particularly since cerivastatin users are likely to have
switched to a different statin on removal. To examine
the impact of discontinuation of cerivastatin, we
repeated the case-control analysis using only the data
prior to 1 January 2001. The resulting all-statins OR was
no longer statistically signiﬁcant and in greater accord
with those for individual statins (see online
supplementary ﬁgure D).
Findings from meta-analyses of a large number of
RCTs leave little doubt that statins do indeed beneﬁt
patients with IHD.35 36 However, the more than 50%
reductions in mortality risk in CPRD and QResearch are
very much greater than the reductions of 20–30%
reported in major trials,37–39 or the overall reduction of
17% from meta-analysis of 92 trials.34 One possibility is
that these observational studies are biased by unmeas-
ured confounding factors, but another is that RCTs
might substantially underestimate the beneﬁt of statins
in the actual population of users.
However, our intention in conducting the research
was more methodological than clinical: to establish
whether analyses of different PCDs would lead to the
same overall clinical conclusions. To this end, we kept all
aspects of the analysis as constant as possible except for
the PCD itself. The closeness of the results suggests that
any variations between the datasets in population
characteristics, data deﬁnitions, data quality and com-
pleteness had only a very minimal impact on the key stat-
istical outputs: the HRs and ORs that are the main
parameters used to inform clinical and policy decision-
making. The few differences in statistical signiﬁcance
Figure 2 Adjusted ORs comparing cases and controls by type and use of statin; CPRD and QResearch studies.
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were principally attributable to the considerably larger
size of the CPRD sample.
Our results also demonstrate that PCD-based studies
can be successfully and independently replicated in
other PCDs. However, this was only possible with the
cooperation of H-C&C, as the original paper did not
include the necessary methodological detail: for
example, the Read and other codes used to deﬁne IHD
and other morbidities; how drug exposures were mea-
sured; the precise speciﬁcation of each covariate; and
the method used to select matched controls. Such
absence of methodological detail is near ubiquitous
throughout the ﬁeld and at least partly attributable to
journal restrictions on paper length. Most scientiﬁc jour-
nals now allow supplementary material to be published
online alongside the main paper, and we would encour-
age researchers to publish their full methods online,
whenever possible, and journal editors to encourage
this. To facilitate this, we have setup an online code-list
repository.40
Our results provide a degree of reassurance about the
validity of PCD-based studies, at least in terms of
research undertaken using CPRD and/or QResearch.
Together with Vinogradova et al’s replication21 of a dif-
ferent clinical topic, the ﬁndings suggest that these two
PCDs produce estimates of treatment effects that are
substantially the same. Combined with replication
studies comparing CPRD and DIN-LINK,20 there is a
nascent body of evidence for wider validity. We also note
that whereas previous replications concerned null (non-
signiﬁcant) ﬁndings, the present study is evidence for
successful replication of a positive intervention effect,
which is arguably a stronger test of agreement. However,
we emphasise that this paper has addressed validity only
in the sense of consistency of statistical results, not the
accuracy of the effect estimates relative to some ‘true’
value or the validity of the clinical conclusions drawn
from these: analyses from both PCDs could conceivably
be biased in the same direction, due to unmeasured
factors common to both or limitations in the analysis
methods themselves.41
Nevertheless, further replication studies similar to ours
are needed. PCDs are used to address a wide range of dif-
ferent kinds of research questions, using a great variety of
designs and analytical methods, and replications of
studies based around other forms of research design
would be particularly informative. Our study used UK
PCDs, which are generally acknowledged to be of higher
quality and completeness than databases available for
most countries, and we would urge researchers in other
countries to undertake similar comparison studies.
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